Loading…
Back To Schedule
Wednesday, June 22 • 1:45pm - 2:45pm
#343: Redefining the Value Proposition for Innovation: Connecting Data, Technology, and Quality to Improve Outcomes

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Application UAN: 0286-0000-22-623-L04-P ; CME 1.00; RN 1.00

Clinical trialists have access to an enormous amount of structured and unstructured data originating from a variety of sources. One of the most significant challenges that biopharma organizations face is how to effectively harness this data to inform decision making and to improve clinical trial outcomes. Biopharma organizations are beginning to leverage technology such as Artificial Intelligence and Machine Learning and utilizing risk-based methods with the intention of driving greater efficiency, improving quality and achieving better outcomes. In this session, we will be exploring the intersection of technology, data and quality and the pursuit of driving higher quality across the clinical trial continuum. Case Studies focused on the use of AI/ML to enable better outcomes and risk-based approaches to manage data quality and improve signal detection will be presented by industry thought leaders in the areas of data science, technology and innovation.

Learning Objectives

Describe the intersection of technology, data and quality and the pursuit of driving higher quality across the clinical trial continuum; Implement AI/ML methods to enable better outcomes and risk-based approaches to manage data quality and improve signal detection.

Chair

Patricia Leuchten

Speaker

A Novel Analytic Method for Improving Signal Detection in Global Trials
Mark Gregory Opler, PhD, MPH

Industry Update
Joseph Geraci, PhD

Industry Update
Jonathan Rowe, PhD, MA, MS


Speakers
avatar for Joseph Geraci

Joseph Geraci

Chief AI Scientist, Netramark Corp, Canada
Dr. Joseph Geraci is a mathematician, medical scientist, and machine learning specialist. He is the founder and Chief AI Scientist of NetraMark Corp which is a technology company focusing on optimizing clinical trials and creating a new taxonomy of disease for drug discovery. He currently... Read More →
avatar for Patricia Leuchten

Patricia Leuchten

Founder, Avoca Group, WCG, United States
Patricia Leuchten is Founder of WCG Avoca. She has more than 30 years of experience in the pharmaceutical industry, leading teams within clinical operations and business development, and as an entrepreneur, building organizations that provide innovative solutions to common industry... Read More →
avatar for Mark Opler

Mark Opler

Chief Research Officer, WCG MedAvante-ProPhase, United States
Dr. Mark Opler is Chief Research Officer at WCG MedAvante-ProPhase Inc., managing and directing global research programs. Dr. Opler has served on the faculties of New York University Medical School and in the Department of Clinical Neuroscience at Columbia University’s College of... Read More →
avatar for Jonathan Rowe

Jonathan Rowe

Principal, Head of R&D Quality and Operations Risk Management, ZS, United States
Jonathan has >25 years in pharma developing medical therapies from clinical, operational, Quality and business perspectives. He is currently a Principal at ZS where he leads the Clinical Development Quality, Operations and Risk Management group. Previously, Jonathan held the position... Read More →

Wednesday June 22, 2022 1:45pm - 2:45pm CDT
Room 179 McCormick Place 2301 South Indiana Avenue Gate 40 Chicago, IL 60616
  03: Data-Tech in Clinical Trials, Session |   01: ClinSafety-PV, Session |   08: RD Quality-Compliance, Session